Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Effectiveness of prolonged-release melatonin in Improving Quality of Sleep in Patients Aged 55 or Over

https://doi.org/10.14412/2074-2711-2016-2-24-30

Full Text:

Abstract

Objective: to evaluate the efficacy of prolonged-release melatonin used in routine practice to improve sleep quality in Russian patients over 55 years of age.

Patients and methods. The results of the multicenter open-label observational study of Circadin (prolonged-release melatonin) efficiency for treatment of insomnia in 36 patients older than 55 yeare presented. The drug was administered at a dose of 2 mg one-two hours before bedtime for 3 weeks.

Results. Treatment with Circadin resulted in statistically significant (p<0.0001) according to pared t-test (95% CI: 4.8; 7.3) improvement of the sleep quality: the mean value of the modified subjective sleep characteristics scale increased from 11.8±2.6 points at baseline to 17.8±2.3 points after 3 weeks of treatment. The modified Questionnaire Scoring Subjective Characteristics of Sleep was grade from 0 (very bad) to 20 (very good) taking into account: the amount of time required to fall asleep, the sleep duration, the number of night awakenings and the general well-being in the morning. An increase of 6 points on a scale from 0 to 20 was considered as clinically relevant. A greater effect was observed in patients with severely impaired sleep quality as well as with low level of depression and anxiety and absence of cognitive impairment. Upon completion of Circadin treatment there were statistically significant improvement (p<0.0001) of attention (the mean value of the symbol-digit coding test increased from 34.2±9.7 to 37.3±10.6 points) and memory (the median value of the short-term verbal memory test increased from 4 points at baseline to 5 points at the study end, p=0.0069).

The drug had a good safety profile; only one adverse event related to study medication (allergic rush) was registered in the study. The absolute majority (91.7%) of the study patients considered Circadin treatment as either effective or very effective.

Conclusion. Taking into consideration the good safety profile of this drug, confirmed in the present study, as well as the ability of the drug to improve cognitive functions, Circadin may be beneficial in patients from 55 years with insomnia complaint.

About the Authors

G. V. Kovrov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991


M. V. Agaltsov
National Research Center for Preventive Medicine, Moscow
Russian Federation
10, Petroverigsky Lane, Build. 3, Moscow 101990


Z. N. Sukmarova
Medical Research and Education Center, M.V. Lomonosov Moscow State University, Moscow
Russian Federation
27, Lomonosovsky Prospect, Build. 10, Moscow 119192


References

1. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008 Oct 15;4(5):487-504.

2. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010 Nov;24(11):1577-601. doi: 10.1177/ 0269881110379307. Epub 2010 Sep 2.

3. Grewal R, Doghramji K. Epidemiology of Insomnia. In: Attarian HP, Schuman C, editors. Clinical Handbook of Insomnia. 2010. P.13-22. www.springer.com/978-1-60327-033-5. Accessed on 03 Jan 2016.

4. Morin CM, Jarrin DC. Epidemiology of Insomnia. Prevalence, Course, Risk Factors, and Public Health Burden. Sleep Med Clin. 2013;(8):281-97.

5. Cardinali DP, Vidal MF, Vigo DE. New developments in the treatment of primary insomnia in elderly patients: focus on prolonged-release melatonin. ChronoPhysiology and Therapy. 2012;(2):67-79.

6. Zisapel N. Development of a Melatonin-Based Formulation for the Treatment of Insomnia in the Elderly. Drug Dev Res. 2000;(50):226-34.

7. Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: A Sleep-Promoting Hormone. Sleep. 1997 Oct;20(10):899-907.

8. Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin Treatment for Age-Related Insomnia. J Clin Endocrinol Metab. 2001 Oct;86(10):4727-30.

9. Guardiola-Lemaоtre B, Quera-Salva MA. Melatonin and the Regulation of Sleep and Circadian Rhythms. P.420-430. In: Kryger MH, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine. 5th edition. Saunders. 2011. 1766 p.

10. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet. 1995 Aug 26;346(8974):541-4.

11. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007 Dec;16(4):372-80.

12. Lemoine P, Garfinkel D, Laudon M, et al. Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. 2011;7:301-11. doi: 10.2147/TCRM.S23036. Epub 2011 Jul 26.

13. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009 Sep;24(5):239-49. doi: 10.1097/YIC.0b013e32832e9b08.

14. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010 Aug 16;8:51. doi: 10.1186/1741-7015-8-51.

15. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007 Oct;23(10):2597-605.

16. Zisapel N, Lemoine P. Efficacy and Safety of Сircadin in the Treatment of Primary Insomnia. US Neurology. 2008;4(1):53-6.

17. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005 Feb;9(1):41-50.

18. Агальцов МВ. Обзор результатов международных клинических исследований применения препарата пролонгированного мелатонина (Циркадин) при нарушениях сна. Эффективная фармакотерапия. Спецвыпуск «Сон и его расстройства». 2013;(12): 38-46. [Agal'tsov MV. An overview of the results of international clinical trials of the sustained￾release melatonin (Circadin) for sleep disorders. Effektivnaya farmakoterapiya. (Suppl. «Son i ego rasstroistva»). 2013;(12): 38-46. (In Russ.)].

19. Assessment Report for Circadin. EMEA/H/C/695. EMEA 2007. http://www.ema.europa.eu/docs/en_GB/docu￾ment_library/EPAR_-_Scientific_Discussion/ human/000695/WC500026808.pdf

20. Cardinali DP, Vigo DE, Oliva N, et al. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis. 2012;1(3):280-91. Epub 2012 Nov 18.

21. Peck JS, LeGoff DB, Ahmed I, Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psychiatry. 2004 Jul-Aug;12(4): 432-6.

22. Арушанян ЭБ. Эпифизарный гормон мелатонин и нарушения познавательной деятельности головного мозга. Русский медицинский журнал. 2006;(9):673-8. [Arushanyan EB. Epiphyseal hormone melatonin and violations of cognitive activity of the brain. Russkii meditsinskii zhurnal. 2006;(9):673-8. (In Russ.)].

23. Рапопорт СИ, Голиченков ВА, редакто- ры. Мелатонин: теория и практика. Москва: Медпрактика-М; 2009. 99 с. [Rapoport SI, Golichenkov VA, editors. Melatonin: teoriya i praktika [Melatonin: theory and practice]. Moscow: Medpraktika-M; 2009. 99 p.]

24. Мендель ВЭ, Мендель ОИ. Мелатонин: роль в организме и терапевтические возможности. Опыт применения препарата Мелаксен в российской медицинской практике. Русский медицинский журнал. 2010;18(6):336-4. [Mendel' VE, Mendel' OI. Melatonin: role in the body and therapeutic possibilities. The experience of use of Melaxen in the Russian medical practice. Russkii meditsinskii zhurnal. 2010;18(6):336-4. (In Russ.)].

25. Бельская ГН, Степанова СБ. Эффективность мелатонина пролонгированного высвобождения в терапии расстройств сна. Русский медицинский журнал. 2014;(22):1622-7. [Bel'skaya GN, Stepanova SB. Effektivnost' The efficacy of prolonged release melatonin in the treatment of sleep disorders. Russkii meditsinskii zhurnal. 2014;(22):1622-7. (In Russ.)].


For citation:


Kovrov G.V., Agaltsov M.V., Sukmarova Z.N. Effectiveness of prolonged-release melatonin in Improving Quality of Sleep in Patients Aged 55 or Over. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):24-30. (In Russ.) https://doi.org/10.14412/2074-2711-2016-2-24-30

Views: 371


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)